

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

NCT07091734

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Michigan
Enrollment	32 participants

Key Eligibility Criteria

Inclusion (6)

- Patients (≥18 years old) with a diagnosis of familial partial lipodystrophy (per protocol)
- Hemoglobin A1c ≤ 7.0% at screening and after 12-week run-in period and
- Triglycerides ≤ 200 Milligrams Per Deciliter (mg/dL) at screening and after 12-week run-in period
- Stable body weight during the 3 months prior to screening visit (no gain or loss of >5% current body weight)
- Diet must have been stable for the prior 3 months (i.e., no major change in macronutrient composition, e.g. starting or stopping diets such as Atkins, paleo, vegetarianism, veganism)
- ... and 1 more (see full listing online)

Exclusion (22)

- Diagnosis of generalized lipodystrophy or acquired lipodystrophy
- Having received treatment with a Glucagon-like peptide (GLP) -1 agonist or Tirzepatide within the past 6 months
- History of previous treatment with metreleptin within the past 3 months
- Pancreatitis within the past 3 months
- Patients with a medical history of bone marrow transplant, use of an immune check-point inhibitor, or central nervous system tumor involving the hypothalamus
- ... and 17 more (see full listing online)

Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States

<https://clinicaltrials.gov/study/NCT07091734>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).